Roth Capital Keeps VBL Therapeutics (VBLT) at 'Buy' Following Q2 Results; Glioblastoma Remains in Focus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Roth Capital Keeps VBL Therapeutics (VBLT) at 'Buy' Following Q2 Results; Glioblastoma Remains in Focus
(NASDAQ: VBLT) Delayed: 0.16 --0 (-0%)
Previous Close $0.16    52 Week High $7.58 
Open $45.66    52 Week Low $2.76 
Day High $0.16    P/E N/A 
Day Low $0.16    EPS $0.00 
Volume 367